CSN Login
Members Online: 6

You are here

Anlotinib: a novel multi-targeting TKI treatment

lobbyist0724's picture
lobbyist0724
Posts: 383
Joined: Sep 2016

It is exciting to see more new treatments being available.

 

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.

https://www.urotoday.com/recent-abstracts/urologic-oncology/renal-cancer/106996-anlotinib-a-novel-multi-targeting-tyrosine-kinase-inhibitor-in-clinical-development.html

Subscribe to Comments for "Anlotinib: a novel multi-targeting TKI treatment"